Related Experiment Videos

Immunohistochemistry of leukotriene C4 in experimental cerebral vasospasm

N Minami1, E Tani, M Yokota

  • 1Department of Neurosurgery, Hyogo College of Medicine, Japan.

Acta Neuropathologica
|January 1, 1991
PubMed

Insights

In canine models, leukotriene C4 (LTC4) in infiltrating inflammatory cells like neutrophils and macrophages is linked to cerebral vasospasm after subarachnoid hemorrhage (SAH). This suggests a key role for these cells in vasospasm development.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Cerebral vasospasm is a dangerous complication following subarachnoid hemorrhage (SAH).
  • The precise mechanisms underlying SAH-induced vasospasm are not fully understood.
  • Leukotriene C4 (LTC4) is implicated in inflammatory and vascular responses.

Purpose of the Study:

  • To investigate the role of leukotriene C4 (LTC4) in experimental cerebral vasospasm.
  • To identify the cellular sources of LTC4 in the basilar artery following subarachnoid hemorrhage (SAH).

Main Methods:

  • A two-hemorrhage canine model was used to induce experimental cerebral vasospasm.
  • Immunohistochemistry was employed to detect LTC4 expression in basilar artery tissues.
  • Histochemical methods were used to characterize infiltrating inflammatory cells.

Main Results:

  • Leukotriene C4 (LTC4) showed strong positivity in the intima and adventitia of normal basilar arteries.
  • Following subarachnoid hemorrhage (SAH), infiltrating neutrophils and macrophages in the basilar artery adventitia were markedly immunoreactive for LTC4.
  • Neutrophil numbers increased over time after SAH, correlating with LTC4 immunoreactivity.

Conclusions:

  • Infiltrating neutrophils and macrophages are the likely primary sources of leukotriene C4 (LTC4) contributing to cerebral vasospasm after SAH.
  • Neurons, ependymal, and arachnoid cells also express LTC4, but astrocytes and oligodendrocytes do not.
  • These findings highlight inflammatory cells and LTC4 as potential therapeutic targets for managing SAH-induced vasospasm.

Related Concept Videos